<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417583</url>
  </required_header>
  <id_info>
    <org_study_id>172030</org_study_id>
    <nct_id>NCT03417583</nct_id>
  </id_info>
  <brief_title>Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients</brief_title>
  <official_title>Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric
      and quality of life battery of scales at baseline. Have these 50 patients complete a formal
      psychiatric assessment with a psychiatrist within 2 weeks of this clinical battery, and the
      results of these 2 types of assessments will be compared to establish the level of agreement
      between clinical rating scales and formal psychiatric assessment.

      Phase B: Continue to follow Phase A cohort longitudinally and administer neuropsychiatric and
      quality of life battery at 6 months, 12 months, and 18 months form baseline. Recruit an
      additional 50 patients, administer the same neuropsychiatric and quality of life battery at
      baseline, implement medication and counseling intervention according to a standard of care
      protocol, and follow up with the same neuropsychiatric and quality of life battery at 6, 12,
      and 18 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As presented to Phase A (control) patient participant:

      &quot;If you are in this study, you will be asked to answer a series of online surveys assessing
      your psychiatric symptoms and quality of life in the presence of a caregiver. These surveys
      will be emailed to your consented caregiver in the week before your in-person visit. You will
      then come to clinic for an in-person assessment of psychiatric and motor symptoms of HD. You
      will also undergo an in-person psychiatric evaluation with a psychiatrist at Vanderbilt who
      works with HD patients. This psychiatric evaluation will take approximately 60 minutes and
      will occur up to 2 weeks before or after your first regular study visit. This involves a
      clinical interview during which a psychiatrist, who is an expert in psychiatric symptoms of
      HD, will ask about your experience with many different symptoms that can be experienced in
      HD. These two in-person evaluations will occur within 2 weeks of each other. You will
      continue to see your neurology provider for routine follow-up, and you will return for
      in-person follow-up assessments at 6 months, 12 months, and 18 months, repeating the online
      surveys prior to each visit.

      Health-Related Quality of Life and Psychiatric Symptom Surveys (This will take approximately
      60-90 minutes):

      You will be asked to answer on-line survey questions about your psychiatric symptoms and
      quality of life in the presence of a caregiver.

        -  The Neuro-QoL scales include 4 subscales created specifically to measure quality of life
           in patients with neurological disease. These scales include 33 total questions which ask
           you to report your anxiety, depression, sense of well-being, and satisfaction with
           social roles within the previous week.

        -  The PROMIS Anger scale includes 8 questions that ask you to rate your symptoms of anger
           in the previous week.

        -  The PROMIS Sleep-Related Impairment short form includes 8 questions that ask about your
           sleep quality and how you feel during the day after sleeping.

        -  The Patient Health Questionnaire- 9 (PHQ-9) includes 9 questions about symptoms of
           depression that you may be experiencing and how these affect you on a daily basis.

        -  The HD Anosognosia Rating Scale includes 8 questions that ask you to assess how you
           perform daily tasks compared to other people of your same age and education level.

        -  Sleep Questionnaire includes 5 questions about your night and daytime sleep habits.

        -  We will also gather background information such as: date of birth, where you live, if
           you have insurance, and your income. You will also be asked about health and medical
           history such as: when you were diagnosed with HD and what medications you are taking.

      Psychiatric and Motor Symptom Assessment (This will take approximately 60 minutes):

        -  The Hamilton Anxiety Rating Scale (HAM-A) asks you to rate the severity of 14 anxiety
           symptoms.

        -  The Problem Behaviors Assessment short form (PBA-s) asks you and your caregiver about
           the frequency and severity of 11 different psychiatric symptoms that can be experienced
           in HD.

        -  The Columbia Suicide Severity Rating Scale includes up to 6 items yes or no questions to
           assess presence and severity of suicidal thoughts.

        -  The Montreal Cognitive Assessment (MOCA) is short test to measure your memory and
           thinking skills.

        -  The United Huntington's Disease Rating Scale (UHDRS) tool is used by HD clinicians to
           measure the presence and severity of your motor symptoms like chorea and walking
           difficulty.

        -  The UHDRS Total Functional Capacity (TFC) scale is used by HD clinicians to rate your
           ability to carry out daily tasks such as household chores or managing finances.&quot;

      As presented to Phase B (protocol) patient participant:

      &quot;If you are in this study, you will be asked to answer a series of online surveys assessing
      your psychiatric symptoms and quality of life in the presence of a caregiver. These surveys
      will be emailed to your consented caregiver in the week before your in-person visit. You will
      then come to clinic for an in-person assessment of psychiatric and motor symptoms of HD. In
      addition, your psychiatric symptoms will be treated according to a systematic protocol
      developed by HD experts that guides treatment decisions based on our current clinical
      standard of care. You will return for in-person follow-up assessment at 6 months, 12 months,
      and 18 months, repeating the online surveys prior to each visit.

      Health-Related Quality of Life and Psychiatric Symptom Surveys (This will take approximately
      60-90 minutes):

      You will be asked to answer on-line survey questions about your psychiatric symptoms and
      quality of life in the presence of a caregiver.

        -  The Neuro-QoL scales include 4 subscales created specifically to measure quality of life
           in patients with neurological disease. These scales include 33 total questions which ask
           you to report your anxiety, depression, sense of well-being, and satisfaction with
           social roles within the previous week.

        -  The PROMIS Anger scale includes 8 questions that ask you to rate your symptoms of anger
           in the previous week.

        -  The PROMIS Sleep-Related Impairment short form includes 8 questions that ask about your
           sleep quality and how you feel during the day after sleeping.

        -  The Patient Health Questionnaire- 9 (PHQ-9) includes 9 questions about symptoms of
           depression that you may be experiencing and how these affect you on a daily basis.

        -  The HD Anosognosia Rating Scale includes 8 questions that ask you to assess how you
           perform daily tasks compared to other people of your same age and education level.

        -  Sleep Questionnaire includes 5 questions about your night and daytime sleep habits.

        -  We will also gather background information such as: date of birth, where you live, if
           you have insurance, and your income. You will also be asked about health and medical
           history such as: when you were diagnosed with HD and what medications you are taking.

      Psychiatric and Motor Symptom Assessment (This will take approximately 60 minutes):

        -  The Hamilton Anxiety Rating Scale (HAM-A) asks you to rate the severity of 14 anxiety
           symptoms.

        -  The Problem Behaviors Assessment short form (PBA-s) asks you and your caregiver about
           the frequency and severity of 11 different psychiatric symptoms that can be experienced
           in HD.

        -  The Columbia Suicide Severity Rating Scale includes up to 6 items yes or no questions to
           assess presence and severity of suicidal thoughts.

        -  The Montreal Cognitive Assessment (MOCA) is short test to measure your memory and
           thinking skills.

        -  The United Huntington's Disease Rating Scale (UHDRS) tool is used by HD clinicians to
           measure the presence and severity of your motor symptoms like chorea and walking
           difficulty.

        -  The UHDRS Total Functional Capacity (TFC) scale is used by HD clinicians to rate your
           ability to carry out daily tasks such as household chores or managing finances.&quot;

      As presented to caregiver participant:

      &quot;If you are involved in this study, you will be asked to assist the HD patient in completing
      a series of online surveys assessing his or her psychiatric symptoms and quality of life. You
      will also be asked to complete an online survey about your experience as a caregiver:

      â€¢ The Traumatic Brain Injury- Care Quality of Life (TBI-CareQOL) Caregiver Strain short form
      includes 6 items which ask you to rate your feelings of stress and strain related to being a
      caregiver.

      All surveys will be emailed to you the week prior to an in-person study visit.

      You will then accompany the HD patient to clinic for an in-person assessment of psychiatric
      and motor symptoms of HD. During this visit you will be asked to answer questions about the
      patient's psychiatric symptoms (see scales below) and offer input on other symptom surveys
      directed to the patient as you would in a normal clinic visit.

        -  The Factor analysis of the frontal systems behavior scale (FrSBe) family-version is a
           46-item scale that asks you to rate characteristics of frontal lobe dysfunction that you
           observe in the HD patient currently and prior to disease onset.

        -  The Problem Behaviors Assessment short form (PBA-s) asks you and the HD patient about
           the frequency and severity of 11 different psychiatric symptoms that can be experienced
           in HD. &quot;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life- Concern with Death and Dying</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the HDQLIFE Concern with Death and Dying scale, which measures concern with death and dying in Huntington's disease patients. The total score will range from 6 to 30, with higher scores indicating greater concern with death and dying.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Meaning and Purpose</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using HDQLIFE Meaning and Purpose scale, which measures feelings of meaning and purpose in Huntington's disease patients. The total score will range from 4 to 20, with higher scores indicating greater feelings of meaning and purpose in life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Ability to Participate in Social Roles and Activities</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the NeuroQoL- Ability to Participate in Social Roles and Activities scale, which measures ability of individuals with neurological conditions to participate in social roles and activities. The total score will range from 8 to 40, with higher scores indicating greater ability to participate in social roles and activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Anxiety</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the NeuroQoL- Anxiety scale, which measures anxiety in individuals with neurological conditions. The total score will range from 8 to 40, with higher scores indicating greater levels of anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Depression</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the NeuroQoL- Depression scale, which measures depression in individuals with neurological conditions. The total score will range from 8 to 40, with higher scores indicating greater levels of depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Positive Affect and Well-Being</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the NeuroQoL- Positive Affect and Well-Being scale, which measures positive affect and sense of well-being in individuals with neurological conditions. The total score will range from 9 to 45, with higher scores indicating a greater sense of well-being.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Satisfaction with Social Roles and Activities</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the NeuroQoL- Satisfaction with Social Roles and Activities scale, which measures satisfaction with social roles and activities in individuals with neurological conditions. The total score will range from 8 to 40, with higher scores indicating greater levels of satisfaction with social roles and activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life- Caregiver Strain</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>This is measured using the TBI-CareQoL- Caregiver Strain scale, which measures health related quality of life in caregivers. The total score will range from 6 to 30, with higher scores indicating greater levels of caregiver strain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Clinical Standard Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocol Intervention Group</intervention_name>
    <description>For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.</description>
    <arm_group_label>Protocol Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient participants:

          -  Diagnosed with HD, either through genetic testing or neurologist's clinical diagnosis

          -  Patient has at least 1 neuropsychiatric symptom, as reported by their HD provider

          -  21 and older will be included, as symptoms of Juvenile HD (in patients 20 years old or
             less) can present differently

          -  Presence of an eligible caregiver who can also participate in the study with them
             because several of the study measures require caregiver report

        Caregivers:

          -  18 years or older

          -  A caregiver will be defined as someone who lives with or has at least weekly contact
             with the HD patient

        Exclusion Criteria:

        Patient participants:

          -  20 years old or younger

          -  Greater than moderate impairment on dementia screening

          -  Lack of a caregiver to provide collateral information and complete caregiver
             assessments will also be excluded

        Caregivers:

          -  Younger than 18 years old and/or have less than weekly contact with the HD patient

          -  Clinical impression of incompetency to answer survey questions as determined by the
             Jessie Sellers, Nurse Practitioner, or the neurologist caring for the HD patient, then
             he or she will not be eligible to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Isaacs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hoadley</last_name>
    <phone>615-875-1257</phone>
    <email>jennifer.hoadley@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>David Isaacs</investigator_full_name>
    <investigator_title>Movement Disorder Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

